Burden of Type 2 and Oral Corticosteroids Related Comorbidities in Severe Asthma Patients from the Gulf Countries: A Comparative Study from The ISAR Registry

Asthma

Impact of Health Insurance Type on Access to Biologics and Systemic Corticosteroid Exposure in Patients With Severe Asthma: A Real-World Study From the Korean Severe Asthma Registry (KoSAR)

Allergy Asthma Immunol Res

Sohn KH, Lee SK, Lee HY, Kim SR, Lee SE, Kim JH, Song WJ, Kim SH, Korean Severe Asthma Registry (KoSAR) Investigators

doi: 10.4168/aair.2026.18.2.192

COMMENTED

Asthma

Clinical Remission in Severe Asthma: A Comparative Analysis of Patients with and Without Biologics from the Swiss Severe Asthma Registry

★ 2 Recommended by Dr. med. Martin Frey, Faculty Member

★ 3 Recommended and commented by Dr Marcus Hesse, Faculty Member

Biomedicines

Jaun F, Boesing M, Lüthi-Corridori G, Bridevaux PO, Charbonnier F, Clarenbach CF, Fellrath JM, Gianella P, Jochmann A, Kern L, Pavlov N, Latshang TD, Von Garnier C, Leuppi JD

doi: 10.3390/biomedicines13123074

Asthma

Real-World Response to Dupilumab as Add-on Therapy in Adults and Adolescents with Type 2 Severe Asthma: A Spanish Cohort Study

J Asthma Allergy

Montoro Ferrer A, Moro Moro MDM, Parra Borreguero FM, Moreno-Ancillo A, Extremera Ortega AM, Galindo-Bonilla PA, Jiménez Lara M, Bravo Nieto JM, Jiménez Arroyo M, Lemus Calderón JA, Espinosa de Los Monteros Garde MJ

doi: 10.2147/JAA.S582686

COMMENTED

Asthma

Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial

★ 3 Recommended by Dr. med. Martin Frey, Faculty Member

★ 2 Recommended and commented by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Wechsler ME, Brightling CE, Brusselle G, Caminati M, Soler T, González EM, Nakwan N, Capala-Szczurko I, Hunter G, Almqvist G, Lal H, Kabelis P, Scrigner P, Matsunaga Y, Molfino N, Ponnarambil SS, SUNRISE study investigators

doi: 10.1016/S2213-2600(26)00076-7

Asthma

Rilzabrutinib for patients with moderate-to-severe asthma with uncontrolled symptoms: a double-blind, placebo-controlled, phase 2 study

Lancet Respir Med

Maspero JF, Pavord ID, Wechsler ME, Busse W, Laidlaw TM, Mróz RM, Liu T, Mikol V, Suratt BT, Gereige J, Mannent L, Martincova R

doi: 10.1016/S2213-2600(25)00439-4

Asthma

Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab Registry

Respir Med

Harvey ES, Hamada Y, Hiles SA, Langton D, Thomas D, McDonald VM, Bardin P, Peters M, Reynolds PN, Upham JW, Blakey J, Bowler S, Chien J, Chung LP, Farah CS, Gillman A, Harrington J, Hew M, Jenkins C, Katelaris CH, Katsoulotos GP, Kritikos V, Lee J, Radhakrishna N, Sivakumaran P, Wark PAB, Gibson PG, Australian Mepolizumab Registry Investigators

doi: 10.1016/j.rmed.2025.108340

Asthma

Osteoporosis in Severe Asthmatic Patients: Data from the Severe Asthma Network in Italy (SANI) Registry

J Clin Med

Latorre M, Costanzo G, Ledda AG, Sambugaro G, Cardini C, Sala I, Oriecuia C, Bagnardi V, Blasi F, Paggiaro P, Canonica GW, Heffler E, Senna G, Firinu D, Puxeddu I, Pini L, Del Giacco S, On Behalf Of The Sani Study Group

doi: 10.3390/jcm14207387

RECOMMENDED

Asthma

Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial

★ 3 Recommended by Dr. med. Martin Frey, Faculty Member

★ 3 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Jackson DJ, Lugogo NL, Gurnell M, Heaney LG, Korn S, Brusselle G, Chanez P, Del Olmo R, Llanos JP, Keeling N, Sałapa K, Cook B, Parulekar AD, Kostikas K, Fogel R, Martin N, Chandarana SN

doi: 10.1016/S2213-2600(25)00359-5

Asthma

Symptom burden to characterise, predict, and prevent asthma attacks: a patient-level meta-analysis of randomised trials and translational prospective studies

Lancet Respir Med

Couillard S, Meulmeester FL, Charland P, Lemaire-Paquette S, Howell I, Celis-Preciado C, Lachapelle P, Heaney LG, Bradding P, Mailhot-Larouche S, Ramakrishnan S, Wechsler ME, Brusselle G, Diver SE, Brightling CE, Castro M, Hanania NA, Jackson DJ, Martin N, Moore A, Howarth P, Hardin ME, Gall R, Holweg CTJ, Dharman V, Beasley RW, Sont JK, Steyerberg EW, Pavord ID, Oxford Asthma Attack Risk Scale Meta-analysis (ORACLE2) Consortium

doi: 10.1016/S2213-2600(26)00150-5

Related content

Impact of Health Insurance Type on Access to Biologics and Systemic Corticosteroid Exposure in Patients With Severe Asthma: A Real-World Study From the Korean Severe Asthma Registry (KoSAR)

Clinical Remission in Severe Asthma: A Comparative Analysis of Patients with and Without Biologics from the Swiss Severe Asthma Registry

Real-World Response to Dupilumab as Add-on Therapy in Adults and Adolescents with Type 2 Severe Asthma: A Spanish Cohort Study

Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial

Rilzabrutinib for patients with moderate-to-severe asthma with uncontrolled symptoms: a double-blind, placebo-controlled, phase 2 study

Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab Registry

Osteoporosis in Severe Asthmatic Patients: Data from the Severe Asthma Network in Italy (SANI) Registry

Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial

Symptom burden to characterise, predict, and prevent asthma attacks: a patient-level meta-analysis of randomised trials and translational prospective studies